REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on discovering, developing, and commercializing next-generation therapeutics for diseases with significant unmet medical needs. The company's current pipeline targets central nervous system, inflammatory, and cardiometabolic diseases. Reviva utilizes a chemical genomics driven technology platform and proprietary chemistry to develop new medicines. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered internally. Reviva Pharmaceuticals, Inc., a Delaware corporation, was incorporated on May 1, 2006, and its subsidiary, Reviva Pharmaceuticals India Pvt. Ltd., was incorporated on December 23, 2014. On December 14, 2020, Reviva Pharmaceuticals Holdings, Inc. (formerly Tenzing Acquisition Corp., a British Virgin Islands exempted company formed on March 20, 2018) completed a business combination with Reviva Pharmaceuticals, Inc., making the latter a wholly owned subsidiary.